华森制药：产品完成境内生产药品备案

Core Viewpoint - The company has completed the domestic production registration of Apsaglarin tablets, which is a response to the aging population trend and aims to enhance the readability and usability of product information [1] Group 1: Product Registration and Compliance - The company has received approval from the National Medical Products Administration for the domestic production registration of Apsaglarin tablets [1] - The registration includes an application for an age-friendly product information leaflet, which features larger font sizes and the introduction of an electronic version [1] Group 2: Social Responsibility and Innovation - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for age-friendly reform, reflecting its commitment to social responsibility [1] - This initiative demonstrates the company's efforts in product and service innovation aimed at the elderly population [1] Group 3: Market Opportunities - The completion of the registration is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through this initiative [1]